Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference
Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference
EMERYVILLE, Calif., Jan. 6, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced that the Company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. Warner Biddle, Chief Executive Officer of Kyverna, will present its 2025 strategic priorities and key milestones during a presentation on Monday, January 13, 2025, at 5:15 p.m. PST.
加利福尼亞州埃默裏維爾,2025年1月6日 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, 納斯達克: KYTX),是一家專注於開發用於自身免疫疾病患者的電芯療法的臨牀階段生物製藥公司,宣佈公司將參加第43屆J.P.摩根醫療健康大會。Kyverna首席執行官Warner Biddle將在2025年1月13日星期一下午5:15(太平洋標準時間)進行演示,介紹其2025年戰略重點和關鍵里程碑。
A live audio webcast of the presentation may be accessed via the Investors section of the Kyverna website at . A replay of the webcast will be available on the website for 30 days following the conference.
該演示的現場音頻網絡廣播可通過Kyverna網站的投資者部分訪問。會議結束後,網絡廣播的重播將在網站上提供30天。
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna's pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
關於Kyverna Therapeutics
Kyverna Therapeutics, Inc.(納斯達克: KYTX)是一家以患者爲中心的臨牀階段生物製藥公司,專注於開發用於遭受自身免疫疾病患者的電芯療法。我們的主要CAR T細胞療法候選藥物KYV-101正在通過臨牀開發,贊助的臨牀試驗覆蓋兩個廣泛的自身免疫疾病領域:風溼病學和神經病學,包括對僵人綜合徵、多發性硬化症和重症肌無力的2期試驗,針對系統性硬化症的1/2期試驗,以及在美國和德國針對狼瘡性腎炎患者的兩個正在進行的多中心1/2期試驗。Kyverna的產品線包括針對B細胞驅動的自身免疫疾病而設計的自體和異體格式的下一代CAR T細胞療法。
For more information, please visit .
欲獲取更多信息,請訪問。 .
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: Kyverna's participation at the 43rd Annual J.P. Morgan Healthcare Conference and the expected discussion of Kyverna's strategic priorities and key anticipated milestones and Kyverna's ongoing clinical trials. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
前瞻性聲明
本新聞稿中關於未來預期、計劃和前景的聲明,以及任何其他涉及非歷史事實的聲明,可能構成「前瞻性聲明」。詞彙,如「預計」、「相信」、「繼續」、「可能」、「估計」、「期待」、「打算」、「可能」、「計劃」、「潛力」、「預測」、「項目」、「應該」、「目標」、「將」、「會」和類似表達,旨在識別前瞻性聲明,儘管並非所有前瞻性聲明都包含這些或類似的識別詞。本新聞稿中的前瞻性聲明包括但不限於與Kyverna參加第43屆J.P.摩根醫療健康大會及預計討論Kyverna的戰略重點和關鍵預期里程碑以及Kyverna正在進行的臨牀試驗相關的聲明。實際結果可能因各種重要因素而與這些前瞻性聲明所指示的結果有重大不同,包括與市場條件相關的問和Kyverna最近提交給美國證券交易委員會的10-K表格年報和10-Q表格季度報告「風險因素」部分討論的其他因素。本新聞稿中包含的任何前瞻性聲明均基於Kyverna管理團隊當前的期望,僅在本文日期時有效,Kyverna特別聲明不承擔更新任何前瞻性聲明的義務,無論是由於新信息、未來事件還是其他原因。
Contact:
Investors: [email protected]
Media: [email protected]
聯繫方式:
投資者: [email protected]
媒體: [email protected]
SOURCE Kyverna Therapeutics
來源 Kyverna Therapeutics
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想讓貴公司的資訊在PRNEWSWIRE.COM上特色展示嗎?
譯文內容由第三人軟體翻譯。
評論(0)
請選擇舉報原因